JP2017514501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514501A5 JP2017514501A5 JP2016566656A JP2016566656A JP2017514501A5 JP 2017514501 A5 JP2017514501 A5 JP 2017514501A5 JP 2016566656 A JP2016566656 A JP 2016566656A JP 2016566656 A JP2016566656 A JP 2016566656A JP 2017514501 A5 JP2017514501 A5 JP 2017514501A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- gene
- exon
- human
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims description 218
- 108090000978 Interleukin-4 Proteins 0.000 claims description 103
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 60
- 102000004388 Interleukin-4 Human genes 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 41
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 39
- 230000001105 regulatory effect Effects 0.000 claims description 38
- 108091081024 Start codon Proteins 0.000 claims description 35
- 101100232919 Homo sapiens IL4 gene Proteins 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims description 12
- 108700024394 Exon Proteins 0.000 claims description 11
- 102000055229 human IL4 Human genes 0.000 claims description 11
- 101100232925 Mus musculus Il4 gene Proteins 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 8
- 238000001467 acupuncture Methods 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 101001033311 Mus musculus Interleukin-4 receptor subunit alpha Proteins 0.000 description 18
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989757P | 2014-05-07 | 2014-05-07 | |
| US61/989,757 | 2014-05-07 | ||
| PCT/US2015/029638 WO2015171861A1 (en) | 2014-05-07 | 2015-05-07 | Humanized il-4 and il-4r alpha animals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235722A Division JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514501A JP2017514501A (ja) | 2017-06-08 |
| JP2017514501A5 true JP2017514501A5 (cg-RX-API-DMAC7.html) | 2018-05-24 |
| JP6640740B2 JP6640740B2 (ja) | 2020-02-05 |
Family
ID=53284509
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566656A Active JP6640740B2 (ja) | 2014-05-07 | 2015-05-07 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2019235722A Active JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2021019538A Active JP7145250B2 (ja) | 2014-05-07 | 2021-02-10 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2022147925A Pending JP2022171841A (ja) | 2014-05-07 | 2022-09-16 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2024150803A Active JP7755699B2 (ja) | 2014-05-07 | 2024-09-02 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235722A Active JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2021019538A Active JP7145250B2 (ja) | 2014-05-07 | 2021-02-10 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2022147925A Pending JP2022171841A (ja) | 2014-05-07 | 2022-09-16 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2024150803A Active JP7755699B2 (ja) | 2014-05-07 | 2024-09-02 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
Country Status (26)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2785538T3 (cg-RX-API-DMAC7.html) * | 2014-05-07 | 2018-08-04 | ||
| BR112016029650A2 (pt) | 2014-06-19 | 2017-10-24 | Regeneron Pharma | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? |
| CN107002226B (zh) * | 2014-09-17 | 2021-03-12 | 欧瑞康表面解决方案股份公司，普费菲孔 | 制备具有改善的耐磨性的双层涂布的切割工具的方法 |
| PL3689140T3 (pl) | 2014-11-24 | 2022-09-05 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| IL286403B2 (en) | 2014-12-05 | 2023-10-01 | Regeneron Pharma | Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene |
| HUE067123T2 (hu) | 2014-12-09 | 2024-10-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| JP6997708B2 (ja) | 2015-11-20 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 |
| SG11201806176PA (en) | 2016-02-04 | 2018-08-30 | Regeneron Pharma | Non-human animals having an engineered angptl8 gene |
| AU2017228293B2 (en) | 2016-02-29 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized Tmprss gene |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018190990A1 (en) | 2017-04-13 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
| EP4276185A3 (en) | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| JP7048051B2 (ja) | 2018-07-11 | 2022-04-05 | 正徳 染井 | 痒みを軽減するアトピー性皮膚炎治療剤 |
| FI3823443T3 (fi) * | 2018-07-16 | 2024-07-25 | Regeneron Pharma | Ditra-taudin jyrsijämallit ja niiden käyttö |
| WO2020074005A1 (en) * | 2018-10-12 | 2020-04-16 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric genes |
| WO2020147829A1 (zh) * | 2019-01-17 | 2020-07-23 | 北京百奥赛图基因生物技术有限公司 | 人源化转基因动物 |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| WO2021018198A1 (en) * | 2019-07-29 | 2021-02-04 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric il33 |
| WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| EP4057807A4 (en) * | 2019-11-11 | 2023-12-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL CONTAINING HUMAN OR CHIMERIC GENES |
| CN114786479B (zh) * | 2019-12-25 | 2023-12-15 | 江苏集萃药康生物科技股份有限公司 | 一种il-15人源化小鼠模型及其用途 |
| CN115175559A (zh) * | 2020-01-28 | 2022-10-11 | 瑞泽恩制药公司 | 包含人源化pnpla3基因座的非人动物及其使用方法 |
| CN111149767B (zh) * | 2020-02-24 | 2021-07-20 | 中南大学湘雅二医院 | 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用 |
| CN113527485B (zh) | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| CN111808882B (zh) * | 2020-09-01 | 2020-12-29 | 北京百奥赛图基因生物技术有限公司 | Il7r基因人源化改造的动物模型的构建方法及其应用 |
| CN111793646B (zh) * | 2020-09-08 | 2021-01-15 | 北京百奥赛图基因生物技术有限公司 | Il1r1基因人源化改造的非人动物的构建方法及其应用 |
| CN111926039B (zh) * | 2020-09-23 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Il-13基因人源化的非人动物的构建方法和应用 |
| KR20230124973A (ko) * | 2020-12-21 | 2023-08-28 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 tslp 유전자, 인간화 tslp 수용체 유전자, 및/또는인간화 il7ra 유전자를 갖는 비인간 동물 |
| CN114835798B (zh) * | 2021-05-28 | 2024-02-23 | 百奥赛图(北京)医药科技股份有限公司 | Cd36基因人源化非人动物的构建方法及应用 |
| WO2024067796A1 (zh) * | 2022-09-28 | 2024-04-04 | 百奥赛图(北京)医药科技股份有限公司 | 一种il5和/或il5ra基因人源化修饰的非人动物 |
| KR20250135248A (ko) * | 2023-01-11 | 2025-09-12 | 리제너론 파아마슈티컬스, 인크. | 규제 준수 자동화된 검정을 위한 시스템 및 방법 |
| WO2025175099A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | A rodent copd model |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| JP2007252370A (ja) * | 2006-02-22 | 2007-10-04 | Institute Of Physical & Chemical Research | Ｉｌ−４初期発現系トランスジェニック非ヒト動物およびその利用 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
| US20120157667A1 (en) * | 2009-06-29 | 2012-06-21 | Qingfeng Chen | Methods Of Producing Humanized Non-Human Mammals |
| JP2013500018A (ja) * | 2009-07-24 | 2013-01-07 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | ゲノム編集のための方法 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| KR102256316B1 (ko) | 2011-02-15 | 2021-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 ｍ－ｃｓｆ 마우스 |
| ES2741649T3 (es) | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| CN104039133B (zh) | 2011-10-28 | 2018-05-04 | 瑞泽恩制药公司 | 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠 |
| CA2853731C (en) | 2011-10-28 | 2021-05-18 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| PT3470432T (pt) * | 2012-08-21 | 2021-12-14 | Regeneron Pharma | Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r |
| CN108782459B (zh) | 2012-09-07 | 2021-11-05 | 再生元制药公司 | 经遗传修饰的非人动物及其使用方法 |
| IL299887B2 (en) | 2012-11-05 | 2024-09-01 | Regeneron Pharma | Genetically modified non-human animals and methods of use thereof |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR102370419B1 (ko) | 2013-09-23 | 2022-03-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
| ES2715949T3 (es) | 2013-10-15 | 2019-06-07 | Regeneron Pharma | Animales con IL-15 humanizada |
| EP3430898A1 (en) | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| WO2015077071A1 (en) | 2013-11-19 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| DK3129400T3 (da) | 2014-04-08 | 2020-06-08 | Regeneron Pharma | Ikke-humane dyr med humaniserede Fc-gamma-receptorer |
| AU2015256299C1 (en) | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 |
-
2012
- 2012-11-22 NO NO12794266A patent/NO2785538T3/no unknown
-
2015
- 2015-05-07 DK DK15727106.5T patent/DK3027015T3/en active
- 2015-05-07 HR HRP20180242TT patent/HRP20180242T1/hr unknown
- 2015-05-07 AU AU2015255977A patent/AU2015255977B2/en active Active
- 2015-05-07 SM SM20180018T patent/SMT201800018T1/it unknown
- 2015-05-07 PT PT157271065T patent/PT3027015T/pt unknown
- 2015-05-07 DK DK17193855.8T patent/DK3281521T3/da active
- 2015-05-07 SG SG11201608570YA patent/SG11201608570YA/en unknown
- 2015-05-07 BR BR112016025745-6A patent/BR112016025745A2/pt not_active Application Discontinuation
- 2015-05-07 EP EP15727106.5A patent/EP3027015B1/en active Active
- 2015-05-07 US US14/706,319 patent/US9565841B2/en active Active
- 2015-05-07 LT LTEP15727106.5T patent/LT3027015T/lt unknown
- 2015-05-07 RS RS20180131A patent/RS57073B1/sr unknown
- 2015-05-07 PT PT171938558T patent/PT3281521T/pt unknown
- 2015-05-07 SI SI201531703T patent/SI3281521T1/sl unknown
- 2015-05-07 KR KR1020227041893A patent/KR102517112B1/ko active Active
- 2015-05-07 MX MX2016014563A patent/MX370672B/es active IP Right Grant
- 2015-05-07 RU RU2016143376A patent/RU2703139C2/ru active
- 2015-05-07 CN CN201910691834.4A patent/CN110269047B/zh active Active
- 2015-05-07 IL IL304841A patent/IL304841B1/en unknown
- 2015-05-07 LT LTEP17193855.8T patent/LT3281521T/lt unknown
- 2015-05-07 IL IL248358A patent/IL248358B2/en unknown
- 2015-05-07 ES ES17193855T patent/ES2887852T3/es active Active
- 2015-05-07 PL PL15727106T patent/PL3027015T3/pl unknown
- 2015-05-07 WO PCT/US2015/029638 patent/WO2015171861A1/en not_active Ceased
- 2015-05-07 PL PL17193855T patent/PL3281521T3/pl unknown
- 2015-05-07 KR KR1020167034170A patent/KR102473565B1/ko active Active
- 2015-05-07 JP JP2016566656A patent/JP6640740B2/ja active Active
- 2015-05-07 SM SM20210560T patent/SMT202100560T1/it unknown
- 2015-05-07 EP EP17193855.8A patent/EP3281521B1/en active Active
- 2015-05-07 SI SI201530162T patent/SI3027015T1/en unknown
- 2015-05-07 CA CA3207834A patent/CA3207834C/en active Active
- 2015-05-07 HR HRP20211455TT patent/HRP20211455T1/hr unknown
- 2015-05-07 CN CN201580036907.6A patent/CN106470545B/zh active Active
- 2015-05-07 HU HUE15727106A patent/HUE038028T2/hu unknown
- 2015-05-07 EP EP21166663.1A patent/EP3906781A1/en active Pending
- 2015-05-07 CA CA2947307A patent/CA2947307C/en active Active
- 2015-05-07 ES ES15727106.5T patent/ES2656529T3/es active Active
- 2015-05-07 HU HUE17193855A patent/HUE055860T2/hu unknown
- 2015-05-07 RS RS20211141A patent/RS62345B1/sr unknown
- 2015-05-07 SG SG10201912354PA patent/SG10201912354PA/en unknown
- 2015-05-07 IL IL297105A patent/IL297105B2/en unknown
- 2015-07-06 US US14/791,978 patent/US9743647B2/en active Active
-
2016
- 2016-10-17 PH PH12016502058A patent/PH12016502058A1/en unknown
-
2017
- 2017-07-14 US US15/649,702 patent/US10588298B2/en active Active
- 2017-09-15 US US15/705,326 patent/US10477842B2/en active Active
-
2018
- 2018-01-15 CY CY20181100040T patent/CY1119773T1/el unknown
-
2019
- 2019-10-07 US US16/594,537 patent/US11109578B2/en active Active
- 2019-12-26 JP JP2019235722A patent/JP6838131B2/ja active Active
-
2021
- 2021-02-10 JP JP2021019538A patent/JP7145250B2/ja active Active
- 2021-08-05 US US17/394,492 patent/US11963521B2/en active Active
- 2021-08-18 AU AU2021218060A patent/AU2021218060C1/en active Active
- 2021-09-14 CY CY20211100805T patent/CY1124605T1/el unknown
-
2022
- 2022-08-30 US US17/823,186 patent/US12310340B2/en active Active
- 2022-09-16 JP JP2022147925A patent/JP2022171841A/ja active Pending
-
2024
- 2024-07-08 AU AU2024204694A patent/AU2024204694A1/en active Pending
- 2024-09-02 JP JP2024150803A patent/JP7755699B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514501A5 (cg-RX-API-DMAC7.html) | ||
| JP7755699B2 (ja) | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 | |
| US10655144B2 (en) | Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells | |
| JP2019047818A5 (cg-RX-API-DMAC7.html) | ||
| RU2648166C1 (ru) | Животные, содержащие гуманизированную дипептидилпептидазу iv (dpp4) | |
| JP2011501652A5 (cg-RX-API-DMAC7.html) | ||
| HRP20251062T1 (hr) | Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala | |
| JP2017213006A5 (cg-RX-API-DMAC7.html) | ||
| JP2019511918A5 (cg-RX-API-DMAC7.html) | ||
| JP2019506897A5 (cg-RX-API-DMAC7.html) | ||
| JP2019505216A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515248A5 (cg-RX-API-DMAC7.html) | ||
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| RU2788523C2 (ru) | ЖИВОТНЫЕ С ГУМАНИЗИРОВАННЫМИ IL-4 И IL-4Rα | |
| Araya et al. | Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model | |
| CN118581158A (zh) | 一种限制型心肌病动物模型的构建方法 | |
| HK40053187A (en) | Humanized il-4 and il-4r alpha animals | |
| RU2020135272A (ru) | Модели заболевания ditra на животных, отличных от человека, и пути их применения | |
| JPWO2006059691A1 (ja) | 抗肥満薬のスクリーニング方法 | |
| CN110564771A (zh) | 脑钙化病模型的制备方法 | |
| JP2005087164A (ja) | ノックアウトマウス | |
| HK1245011A1 (en) | Humanized il-4 and il-4r alpha animals |